Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors. Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.
Capitalising on the lack of quality investment material available in conventional financial media on the biotech sector, Biotech Capital provides institutional-quality content which is also accessible to ultra-high net worth, high net worth, sophisticated and professional investors. Our platform is also utilised by investors to keep updated on all Biotechnology and index live prices.
In unison with our leading editorial content, Biotech Capital gives companies the ability to communicate with investors, in an unprecedented manner, via sophisticated video and audio video interviews.
Aside from our digital content, we also connect biotech companies with investors via our Biotech Capital conferences; the largest Biotech conferences in London. They are international in nature and involve six companies presenting to an audience of 250 - 300 investors. Post-presentation, a catered networking period is hosted where directors and asset managers converse over lunch.